From 19 to 21 January 2011, Rift Valley Fever Vaccine Development, Progress and Constraints, an international expert workshop organized by the Food and Agriculture Organization of the United Nations (FAO) and the Central Veterinary Institute of Wageningen University and Research Centre (CVI-WUR) convened 34 leading experts and policy makers in Rift Valley fever (RVF) virology, epidemiology and vaccine development. The main objective of the meeting was to gain consensus on the desired features of novel veterinary Rift Valley fever virus vaccines and to discuss how incentives can be established to make sure that these vaccines come to market. The views from international organizations and industry on the current and future control of RVF were presented and the stages of development of candidate vaccines were reported. The desired characteristics of vaccines for application in different areas of the world were debated as well as the advantage of applying DIVA vaccines. The necessity of establishing emergency vaccine banks was discussed as well as the need for a human vaccine to protect laboratory workers, farmers and veterinarians. It was concluded that a "level playing field" should be established to facilitate rational selection of novel vaccines and that incentives for vaccine manufacturers should be established to ensure that these vaccines come to market. A total of 11 recommendations to policy makers, industry and the scientific community were formulated that should facilitate this process.
The Rift Valley Fever Vaccine Development, Progress and Constraints workshop, was held at the FAO headquarters in Rome, Italy, and was sponsored by the Global Framework for the Progressive Control of Transboundary Animal Diseases (GF-TADS) - a joint initiative of FAO and the World Organisation for Animal Health (OIE) that combines the strength of both organizations in the fight against transboundary animal diseases worldwide. The workshop was supported by the Netherlands Ministry of Economic Affairs, Agriculture and Innovation, and the US Centers for Disease Control and Prevention (CDC), with participation of the World Health Organization (WHO) and the International Atomic Energy Agency (IAEA).
List of documents
- List of participants
- Photo of the group participants
- Final report: Rift Valley fever vaccine development, progress and constraints (PDF)